Real-world comparison of Ixazomib, lenalidomide and dexamethasone vs lenalidomide and dexamethasone in relapsed and refractory multiple myeloma

We have performed a face to face comparison of all-oral triplet ixazomib, lenalidomide and dexamethasone (IRD) versus lenalidomide and dexamethasone (RD) in patients with relapsed and refractory multiple myeloma (RRMM) in the routine clinical practice. The primary endpoint was progression free survival (PFS), secondary end points included response rates and overall survival (OS).